Mazor Robotics Receives Purchase Orders for Three Renaissance® Systems in Asia

- Company receives purchase order for two systems from China and one system from Taiwan -

CAESAREA, Israel - December 9, 2014 - Mazor Robotics Ltd. (NASDAQGM: MZOR; TASE: MZOR), a developer of innovative guidance systems and complementary products, today announced that it received a purchase order for two Renaissance systems from its distribution partner in China, Cicel (Beijing) Science & Technology CO. Ltd., reflecting the first systems sold into the Chinese market following the receipt of the China Food and Drug Administration (CFDA) approval to market the Renaissance system in China, in September 2014.

The Company also received a purchase order for one Renaissance system from its distribution partner in Taiwan, Pinnaclemed CO. Ltd. Subject to certain closing conditions, the system is expected to be installed at a newly opened spine hospital in Taiwan. This is the third system purchase by Pinnaclemed Co. Ltd. and will be the third Renaissance system in Taiwan.

"Entering the Chinese market is a significant achievement for Mazor and expands our growing presence in the fastest growth region for Renaissance outside of the U.S. market. We look forward to working closely with our distribution partner to raise the awareness of Renaissance throughout the country highlighting the benefits of the system to leading healthcare facilities. An order for a third system in Taiwan is encouraging as the two systems currently in use have some of the highest utilization rates demonstrating the degree of surgeon comfort, system performance and patient outcome," commented Ori Hadomi, Mazor's Chief Executive Officer.

Today's announcement was made in accordance with Mazor Robotics' disclosure policy of announcing system sales that have a strategic impact on the business, such as new markets, academic institutions and national accounts.

About Mazor

Mazor Robotics (TASE: MZOR; NASDAQGM: MZOR) believes in healing through innovation by developing and introducing revolutionary robotic-based technology and products aimed at redefining the gold standard of quality care. Mazor Robotics Renaissance® Guidance System enables surgeons to conduct spine and brain procedures in a more accurate and secure manner. For more information, please visitwww.MazorRobotics.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Any statements in this release about future expectations, plans or prospects for the Company, including without limitation, statements regarding the expectations for growth in system sales and recurring revenue, the Company's expected sales in 2016, and other statements containing the words "believes," "anticipates," "plans," "expects," "will" and similar expressions are forward-looking statements. These statements are only predictions based on Mazor's current expectations and projections about future events. There are important factors that could cause Mazor's actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Those factors include, but are not limited to, the impact of general economic conditions, competitive products, product demand and market acceptance risks, reliance on key strategic alliances, fluctuations in operating results, and

other factors indicated in Mazor's filings with the Securities and Exchange Commission (SEC) including those discussed under the heading "Risk Factors" in Mazor's annual report on Form 20-F filed with the SEC on April 29, 2015 and in subsequent filings with the SEC. For more details, refer to Mazor's SEC filings. Mazor undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in our expectations, except as may be required by law.

U.S. Contacts: EVC Group

Michael Polyviou/Doug Sherk - Investors

mpolyviou@evcgroup.com; dsherk@evcgroup.com

212.850.6020; 646-445-4800

David Schemelia - Media

dave@evcgroup.com

646.201.5431

https://investors.mazorrobotics.com/press-releases?item=111